Larimar Therapeutics
Tracked across 2 events · 12 articles · First seen Jun 26, 2026 · Last active Jul 05, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Larimar Therapeutics is hosting an investor event to provide updates on its Nomlab of USP clinical development program, including regulatory updates and data from an ongoing long-term study for Friedreich s ataxia. This event is crucial for the company to communicate its progress and future plans to investors.
Jun 26, 2026 · 6 articles
Regulatory
Impact: Larimar Therapeutics is under investigation by Pomerantz LLP for alleged securities fraud and unlawful business practices related to its drug nomlabofusp, which has shown safety concerns in clinical trials, leading to significant stock price drops.
Jul 01, 2026 · 6 articles
100
Larimar Therapeutics host investor eventLarimar Therapeutics hosts...
100
Pomerantz LLP investigates claims Larimar TherapeuticsPomerantz Investigates...
90
Larimar Therapeutics disclosed anaphylaxisPomerantz Investigates...
60
Larimar Therapeutics issued press releasePomerantz Investigates...
ERGEN INTELLIGENCE
Track Larimar Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard